147 related articles for article (PubMed ID: 2726237)
21. [Effect of prophylactic intravesical instillation of BCG for superficial bladder cancer].
Segawa N; Inamoto T; Nomi H; Ibuki N; Azuma H; Katsuoka Y
Hinyokika Kiyo; 2009 Apr; 55(4):175-80. PubMed ID: 19462820
[TBL] [Abstract][Full Text] [Related]
22. Clinicopathological evaluation of repeated courses of intravesical bacillus Calmette-Guerin instillation for preventing recurrence of initially resistant superficial bladder cancer.
Okamura T; Tozawa K; Yamada Y; Sakagami H; Ueda K; Kohri K
J Urol; 1996 Sep; 156(3):967-71. PubMed ID: 8709375
[TBL] [Abstract][Full Text] [Related]
23. [Adjuvant local BCG-immunotherapy in patients with urothel cancer of the bladder (author's transl)].
Flamm J; Grof F
Wien Med Wochenschr; 1981 Oct; 131(20):501-6. PubMed ID: 7314632
[TBL] [Abstract][Full Text] [Related]
24. [Immunotherapy in superficial bladder carcinoma].
Ríos González E; Martínez-Piñeiro Lorenzo L; Martínez-Piñeiro Caramés JA; de la Peña Barthel JJ
Arch Esp Urol; 2000 Dec; 53(10):879-92. PubMed ID: 11213392
[TBL] [Abstract][Full Text] [Related]
25. [Bacillus Calmette Guerin as adjuvant treatment for superficial bladder tumors using two different therapeutic schemes].
Iturralde Codina A; Beyríe Tamayo W; Gozá León F; Muñoz YI
Arch Esp Urol; 2004; 57(6):606-18. PubMed ID: 15382436
[TBL] [Abstract][Full Text] [Related]
26. The results of concurrent chemo-radiotherapy for recurrence after treatment with bacillus Calmette-Guérin for non-muscle-invasive bladder cancer: is immediate cystectomy always necessary?
Wo JY; Shipley WU; Dahl DM; Coen JJ; Heney NM; Kaufman DS; Zietman AL
BJU Int; 2009 Jul; 104(2):179-83. PubMed ID: 19154448
[TBL] [Abstract][Full Text] [Related]
27. [Results of BCG in the treatment of pTa and pT1 bladder tumors. Evaluation of a long protocol using 75 mg of Pasteur strain BCG].
Ayed M; Ben Hassine L; Ben Slama R; Chelbi N; Ghozzi S; Drissi H; Jemni M; Chebil M
Prog Urol; 1998 Apr; 8(2):206-10. PubMed ID: 9615929
[TBL] [Abstract][Full Text] [Related]
28. Antibody responses to Bacillus Calmette-Guérin during immunotherapy in bladder cancer patients.
Winters WD; Lamm DL
Cancer Res; 1981 Jul; 41(7):2672-6. PubMed ID: 7018669
[TBL] [Abstract][Full Text] [Related]
29. Advances in the treatment of superficial bladder cancer: optimizing BCG immunotherapy. Introduction.
Lamm DL
Eur Urol; 1995; 27 Suppl 1():1. PubMed ID: 7750524
[No Abstract] [Full Text] [Related]
30. [Polyarthritis as a rare complication in BCG immunoprophylaxis of urinary bladder cancer].
Varentsov GI; Zakhmatov IuM; Kornev AI; Otvetchikov IN
Urologiia; 1999; (5):29-30. PubMed ID: 11150151
[TBL] [Abstract][Full Text] [Related]
31. [Prophylactic effects of zhuling and BCG on postoperative recurrence of bladder cancer].
Yang DA; Li SQ; Li XT
Zhonghua Wai Ke Za Zhi; 1994 Jul; 32(7):433-4. PubMed ID: 7842985
[TBL] [Abstract][Full Text] [Related]
32. [Clinical investigation on the effect of intravesical instillation of antifibrinolytic agents with bacillus Calmette-Guerin on preventing bladder cancer recurrence].
Ding GQ; Shen ZJ; Lu J; Jin XD; Chen J; Shi SF
Zhonghua Wai Ke Za Zhi; 2005 Nov; 43(22):1457-60. PubMed ID: 16318813
[TBL] [Abstract][Full Text] [Related]
33. Restaging transurethral resection of high risk superficial bladder cancer improves the initial response to bacillus Calmette-Guerin therapy.
Herr HW
J Urol; 2005 Dec; 174(6):2134-7. PubMed ID: 16280743
[TBL] [Abstract][Full Text] [Related]
34. Marker tumour responses to the sequential combination of intravesical therapy with mitomycin-C and BCG-RIVM in multiple superficial bladder tumours. Report from the European Organisation for Research and Treatment on Cancer-Genitourinary Group (EORTC 30897).
Van der Meijden AP; Hall RR; Macaluso MP; Pawinsky A; Sylvester R; Van Glabbeke M
Eur Urol; 1996; 29(2):199-203. PubMed ID: 8647147
[TBL] [Abstract][Full Text] [Related]
35. [Treatment of superficial tumors of the bladder with bacillus Calmette-Guérin].
Ackermann D; Schnyder M; Bandelier D; Studer UE
J Urol (Paris); 1986; 92(1):33-8. PubMed ID: 3722851
[TBL] [Abstract][Full Text] [Related]
36. Cystectomy in patients with high risk superficial bladder tumors who fail intravesical BCG therapy: pre-cystectomy prostate involvement as a prognostic factor.
Huguet J; Crego M; Sabaté S; Salvador J; Palou J; Villavicencio H
Eur Urol; 2005 Jul; 48(1):53-9; discussion 59. PubMed ID: 15967252
[TBL] [Abstract][Full Text] [Related]
37. [Results of chemoimmune prophylaxis of superficial bladder carcinoma (author's transl)].
Adolphs HD; Helpap B
Urologe A; 1982 Jan; 21(1):29-33. PubMed ID: 7200654
[TBL] [Abstract][Full Text] [Related]
38. Low dose Pasteur bacillus Calmette-Guerin regimen in stage T1, grade 3 bladder cancer therapy.
Hurle R; Losa A; Ranieri A; Graziotti P; Lembo A
J Urol; 1996 Nov; 156(5):1602-5. PubMed ID: 8863547
[TBL] [Abstract][Full Text] [Related]
39. Treatment of superficial bladder cancer.
Morales A
Can Med Assoc J; 1980 May; 122(10):1133-8. PubMed ID: 6770987
[TBL] [Abstract][Full Text] [Related]
40. [BCG and radiotherapy: the compatibility of 2 conservative treatments for cancer of the urinary bladder].
Sánchez-Martín FM; Palou Redorta J; Regalado Pareja R; Rubio Briones J; Villavicencio Mavric H; Vicente Rodríguez J
Arch Esp Urol; 1999 Sep; 52(7):749-58. PubMed ID: 10540765
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
